Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?

被引：4
|
作者：
Takahari, Daisuke [1 ]
Chin, Keisho [1 ]
Yamaguchi, Kensei [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 24期
关键词：
first-line chemotherapy; gastric cancer; pembrolizumab monotherapy; TAS-118 plus oxaliplatin; SOL; DOUBLE-BLIND; PHASE-III; CISPLATIN; NIVOLUMAB; S-1;
D O I：
10.2217/fon-2020-0421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1797 / 1799
页数：3
相关论文
共 50 条
  • [41] Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer
    Xu, Mengli
    Meng, Xiangrui
    Lu, Yao
    Wang, Feng
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (02) : 548 - 558
  • [42] Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    Miles, D. W.
    de Haas, S. L.
    Dirix, L. Y.
    Romieu, G.
    Chan, A.
    Pivot, X.
    Tomczak, P.
    Provencher, L.
    Cortes, J.
    Delmar, P. R.
    Scherer, S. J.
    BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1052 - 1060
  • [43] Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer
    Otsuka, Ryo
    Iwasa, Satoru
    Yanai, Takako
    Hirano, Hidekazu
    Shoji, Hirokazu
    Honma, Yoshitaka
    Okita, Natsuko
    Takashima, Atsuo
    Kato, Ken
    Hashimoto, Hironobu
    Sekiguchi, Masatoshi
    Makino, Yoshinori
    Boku, Narikazu
    Yamaguchi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (04) : 595 - 601
  • [44] Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients
    Yuji Mishima
    Satoshi Matsusaka
    Keisho Chin
    Mariko Mikuniya
    Sayuri Minowa
    Tomoko Takayama
    Harumi Shibata
    Ryoko Kuniyoshi
    Mariko Ogura
    Yasuhito Terui
    Nobuyuki Mizunuma
    Kiyohiko Hatake
    Targeted Oncology, 2017, 12 : 341 - 351
  • [45] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
    Morimoto, Kosuke
    Moriwaki, Kensuke
    Shimozuma, Kojiro
    Nakayama, Takeo
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (12) : 1188 - 1197
  • [46] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
    Kosuke Morimoto
    Kensuke Moriwaki
    Kojiro Shimozuma
    Takeo Nakayama
    Journal of Gastroenterology, 2023, 58 : 1188 - 1197
  • [47] Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
    Zielinski, Christoph
    Lang, Istvan
    Beslija, Semir
    Kahan, Zsuzsanna
    Inbar, Moshe J.
    Stemmer, Salomon M.
    Anghel, Rodica
    Vrbanec, Damir
    Messinger, Diethelm
    Brodowicz, Thomas
    BRITISH JOURNAL OF CANCER, 2016, 114 (02) : 163 - 170
  • [48] First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
    Esen, Selin Akturk
    Ergun, Yakup
    Erol, Cihan
    Arikan, Rukiye
    Er, Muhammed Muhiddin
    Atci, Muhammed Mustafa
    Topcu, Atakan
    Ucar, Gokhan
    Akagunduz, Baran
    Aykan, Musa Baris
    Ozen, Mirac
    Baytemur, Naziyet Kose
    Ozcelik, Melike
    Sahin, Elif
    Guven, Denizcan
    Menekse, Serkan
    Ak, Naziye
    Teker, Fatih
    Kut, Engin
    Sakalar, Teoman
    Alan, Ozkan
    Kacan, Turgut
    Turhal, Nazim Serdar
    Kilickap, Saadettin
    Turker, Sema
    Sendur, Mehmet Ali Nahit
    Kostek, Osman
    Karaagac, Mustafa
    Sakin, Abdullah
    Turk, Haci Mehmet
    Caglayan, Dilek
    Cihan, Sener
    Acikgoz, Yusuf
    Uncu, Dogan
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2022, 22 (05) : 818 - 825
  • [49] Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer
    Zhang, Zhening
    Xie, Tong
    Wang, Yingxuan
    Shen, Lin
    Zhang, Xiaotian
    Peng, Zhi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [50] Predictive role of inflammatory markers for the efficacy of first-line immunotherapy plus chemotherapy in advanced gastric cancer
    Chenming Zhong
    Ying Yuan
    Yue Jiang
    Guanglei Qiao
    Zhoufeng Deng
    Zimei Liu
    Liping Yu
    Hongjian Lin
    Jiuang Mao
    Lijun Ma
    Jianjun Zhang
    Discover Oncology, 16 (1)
12345